DocUpdate is a free HIPAA-compliant digital assistant built by physicians for physicians. Their tools, including an intelligent prescribing assistant, AI medical translator for 23+ languages, and pharmaceutical concierge, are designed to give clinicians time back. More at https://docupdate.onelink.me/j4xR/DermPCP

Last issue we stayed disciplined with the red leg: one leg or two, purulent or not, and the restraint to treat narrower and shorter than instinct wants.

This week we swing to the opposite temptation…

Microneedling is a treatment patients arrive already sold on, convinced it will erase acne scars, wrinkles, and the last decade off their face.

It reaches your exam room as a question that sounds simple:

does it work, and should I do it.

The honest answer is neither miracle nor fluff.

Microneedling has a defensible evidence base for a few specific problems, a supporting role in a few more, and a much thinner case for most of what the marketing promises.

The bigger issue is that the version studied in trials is often not the version sold at the medspa down the street, where the real risk usually comes from what gets added to the needles rather than the needles themselves.

Here is the version worth repeating in the exam room.

Five counseling habits turn a straightforward answer into a misleading one. Here is each, and how to reset it.

The mistake: Giving a blanket verdict when a patient asks whether microneedling works.

Why it happens: The word sounds like one procedure, so it invites one answer, and the marketing sells it as a cure-all for everything from pores to scars to hair.

The evidence: The strength of the data tracks the indication, and the spread is wide.

For atrophic acne scars, microneedling as monotherapy shows consistent improvement across multiple randomized trials and systematic reviews, with a low rate of adverse effects and reasonable tolerability in darker skin (systematic review and meta-analysis, JAAD, 2019). This is the strongest indication.

For androgenetic alopecia, microneedling added to topical minoxidil outperforms minoxidil alone across several meta-analyses, making it one of the better-supported add-on therapies for hair loss (meta-analysis, Arch Dermatol Res, 2025). The benefit is in the combination, not in needling alone.

For melasma, microneedling is an adjunct that improves delivery of agents such as tranexamic acid, not a standalone fix (systematic review, 2025).

For general anti-aging or wrinkle reduction as a solo treatment, the case is thin: small split-face studies, short follow-up, frequent industry funding, and outcomes often bundled with topical growth factors, which makes the independent effect of the needling hard to isolate.

Practical tip: Ask what the patient wants to treat before you answer. A workable script: "For acne scars, the evidence is reasonably good. For hair loss, it helps when it is added to minoxidil. For erasing wrinkles on its own, the promise runs well ahead of the data."

The mistake: Endorsing the version layered with vitamin C serums, growth factor cocktails, or platelet-rich plasma as if the add-ons were a free bonus.

Why it happens: The channels are marketed as a delivery route, and "natural" or "your own blood" sounds inherently low-risk.

The evidence: The FDA is explicit that microneedling devices are not cleared to deliver cosmetics, topical products, vitamin solutions, drugs, or platelet-rich plasma into the skin (FDA, Microneedling devices). A product formulated for the skin surface behaves differently once it is needled into the dermis. Case reports and a systematic review describe sarcoidal and foreign-body granulomatous reactions appearing weeks to months after microneedling with vitamin C and other cosmeceuticals, sometimes needing intralesional steroids or prolonged treatment (JAAD Case Reports, 2023).

Sterility of the setting matters even more than the serum. The CDC documented a cluster of HIV infections among clients of an unlicensed New Mexico spa who received platelet-rich plasma microneedling facials between 2018 and 2023, the first documented HIV transmission through cosmetic injection services. It was traced to unsafe infection control, including blood tubes stored in a kitchen refrigerator, not to the concept of microneedling itself (CDC MMWR, 2024).

Practical tip: When a patient describes a serum-heavy treatment or a "vampire facial," two questions matter: what is being applied, and whether the setting uses single-use sterile equipment. A licensed clinician with a sterile device is a different risk category than a medspa improvising with unlabeled blood tubes.

The mistake: Telling a patient a drugstore dermaroller will do what a clinic device does, or that it is automatically safe because it is sold for home use.

Why it happens: The devices look alike and cost a fraction of a clinic series.

The evidence: Depth is the divider. At-home rollers typically reach 0.25 to 0.5mm, enough to enhance topical penetration but generally too shallow to drive the dermal collagen remodeling that improves scars. Clinic devices reach deeper, into the dermis where fibroblasts live. Rollers also enter at an angle and can tear rather than puncture cleanly, and short blunt rollers marketed only for exfoliation are not regulated as medical devices at all (FDA, Microneedling devices). Home use adds sterility and technique risk, and repeated use of dull needles damages skin. Patients with darker skin, roughly Fitzpatrick IV to VI, carry a higher risk of post-inflammatory hyperpigmentation, which argues for the shortest effective depth and careful sun protection rather than aggressive self-treatment.

Practical tip: Frame it as tool versus treatment. A 0.25mm home roller is reasonable for light maintenance and better serum uptake. For acne scars, hyperpigmentation, or anything a patient actually wants corrected, that is a clinic procedure with a professional who can adjust depth and keep the field sterile.

The mistake: Reflexively deferring microneedling because a patient recently took, or is taking, isotretinoin.

Why it happens: The historical teaching, driven by concern for abnormal scarring, was to wait six to twelve months after isotretinoin before any resurfacing procedure.

The evidence: That blanket delay is not well supported for microneedling. A dermatology task force and subsequent systematic reviews concluded that microneedling, including fractional radiofrequency microneedling, can be performed safely during or soon after isotretinoin, without a signal for keloids, delayed healing, or hypertrophic scarring (task force guidelines, J Cutan Aesthet Surg, 2017; systematic review, 2024). Fully ablative lasers and mechanical dermabrasion remain the procedures to postpone. A personal or family history of keloids still warrants caution and a test area regardless of isotretinoin.

Practical tip: Recent or current isotretinoin is not by itself a reason to postpone microneedling. Screen for keloid tendency, which is the more relevant risk, and route those patients to a dermatologist before any controlled-injury procedure.

The mistake: Waving a patient toward microneedling without checking the short list of things that make it a poor idea.

Why it happens: It is marketed as low-risk and suitable for everyone, so screening feels unnecessary.

The evidence: Microneedling creates open channels, so it is contraindicated over active skin infection, active inflammatory acne or open lesions in the treatment field, and unstable inflammatory dermatoses, and it warrants caution with bleeding disorders or anticoagulation, immunosuppression, and pregnancy. Keloid history is the standout, since controlled injury can trigger abnormal scarring in susceptible patients. Radiofrequency microneedling adds its own profile: the FDA's October 2025 safety communication flagged burns, scarring, fat loss, disfigurement, and nerve damage, most tied to operator inexperience and aggressive settings, and stressed that it is a medical procedure, not a home treatment (FDA Safety Communication, 2025).

Practical tip: A one-minute screen covers it: active infection or acne in the area, keloid history, bleeding or clotting issues, immunosuppression, pregnancy. Any yes, and the patient belongs with a dermatologist rather than a walk-in medspa. For radiofrequency microneedling specifically, operator experience is part of the safety profile, not a detail.

Interested in reaching our 8,000+ subscribers?

Click here to learn more!

https://go.dermforprimarycare.com/newsletter-sponsor-lp 

We have created this FREE Guide for you:

Microneedling is a quiet test of expectation management. Patients rarely arrive asking whether it works. They arrive having already decided, and the better outcome usually comes from a calmer conversation rather than a firmer opinion: what are we treating, what is going into the skin, and who is holding the device.

Get that right and you spare a lot of patients a granuloma, a disappointment, or a treatment that was never going to touch the thing they wanted fixed.

Next issue we turn from the cosmetic to the everyday and take on [next issue topic]. See you then.

Stay curious and keep translating science into realistic hope.

Have a topic you'd like us to cover? Reply to this email.

DERM Community | Derm for Primary Care Team